Immunovant (Nasdaq:IMVT) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

IMVT 주식 개요

는 임상 단계의 바이오 제약 회사로 자가 면역 질환 치료를 위한 단일 클론 항체를 개발합니다.

IMVT 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	0/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 55.7% 에서 거래

분석가들은 주가가 87.6% 상승할 것이라는 데 동의합니다.

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

지난 3개월간 상당한 내부자 매도

지난 1년 동안 주주가 희석되었습니다.

Immunovant, Inc. 경쟁사

Mirati Therapeutics

NasdaqGS:MRTX

US$4.1b

Avidity Biosciences

NasdaqGM:RNA

US$4.1b

Turning Point Therapeutics

NasdaqGS:TPTX

US$3.8b

Alkermes

NasdaqGS:ALKS

US$4.2b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Immunovant
과거 주가
현재 주가	US$27.32
52주 최고치	US$45.58
52주 최저치	US$18.16
베타	0.72
11개월 변경	-5.63%
3개월 변경 사항	-12.49%
1년 변경 사항	37.08%
33년 변화	139.44%
5년 변화	178.78%
IPO 이후 변화	174.57%

최근 뉴스 및 업데이트

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Apr 19

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

Apr 04

Recent updates

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Jan 12

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Sep 28

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Jun 14

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Mar 08

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Nov 06

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Oct 17

Immunovant stock down on raising $75M though equity capital

Oct 04

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Aug 06

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Apr 06

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Jun 20

Immunovant EPS beats by $0.04

Jun 01

argenx rise even as Immunovant pauses the trial for anti-FcRn therapy

Feb 03

Immunovant slips 7% on voluntary hold of IMVT-1401 dosing

Feb 02

Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management

Jan 14

Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?

Dec 30

Immunovant (IMVT) Investor Presentation - Slideshow

Nov 16

주주 수익률

	IMVT	US Biotechs	US 마켓
7D	5.1%	0.1%	0.5%
1Y	37.1%	9.8%	23.7%

수익률 대 산업: IMVT 지난 1년 동안 6.7 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: IMVT 지난 1년 동안 23.3 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is IMVT's price volatile compared to industry and market?
IMVT volatility
IMVT Average Weekly Movement	6.0%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	2.8%

안정적인 주가: IMVT 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: IMVT 의 주간 변동성은 지난 1년 동안 15% 에서 6% 로 감소했습니다.

회사 소개

설립	직원	CEO	웹사이트
n/a	207	Pete Salzmann	immunovant.com

임상 단계의 바이오 제약 회사인 이뮤노반트는 자가 면역 질환 치료를 위한 단일 클론 항체를 개발하는 회사입니다. 이 회사는 중증 근무력증, 갑상선 안질환, 만성 염증성 탈수초성 다발성 신경병증, 그레이브스병, 온난성 자가면역 용혈성 빈혈 치료를 위해 신생아 단편 결정화 수용체를 표적으로 하는 새로운 완전 인간 단일 클론 항체인 바토클리맙을 개발하고 있습니다. 이뮤노반트는 미국 뉴욕에 본사를 두고 있습니다.

Immunovant, Inc. 기본 사항 요약

Immunovant 의 수익과 매출은 시가총액과 어떻게 비교하나요?
IMVT 기본 통계
시가총액	US$3.99b
수익(TTM)	-US$259.34m
수익(TTM)	n/a

0.0x

P/S 비율

-15.4x

P/E 비율

IMVT 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
IMVT 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$259.34m
수익	-US$259.34m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.78
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

IMVT 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

IMVT 주식 개요

보상

위험 분석

Immunovant, Inc. 경쟁사

NasdaqGS:MRTX

US$4.1b

NasdaqGM:RNA

US$4.1b

NasdaqGS:TPTX

US$3.8b

NasdaqGS:ALKS

US$4.2b

가격 내역 및 성능

최근 뉴스 및 업데이트

CEO & Director recently sold US$479k worth of stock

CEO & Director recently sold US$990k worth of stock

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

CEO & Director recently sold US$486k worth of stock

New major risk - Revenue and earnings growth

Recent updates

CEO & Director recently sold US$479k worth of stock

CEO & Director recently sold US$990k worth of stock

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

CEO & Director recently sold US$486k worth of stock

New major risk - Revenue and earnings growth

Immunovant: An Intriguing And Developing Story

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates

Independent Director recently sold US$491k worth of stock

Independent Director notifies of intention to sell stock

Immunovant, Inc. Announces Initial Data from 600 Mg MAD Cohort of A Phase 1 Clinical Trial of IMVT-1402 in Healthy Adults

CEO & Director recently sold US$532k worth of stock

Immunovant, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Immunovant, Inc. announced that it expects to receive $169.999992 million in funding from Roivant Sciences Ltd.

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant, Inc. Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Price target increased by 17% to US$34.42

CEO & Director recently sold US$1.3m worth of stock

Chief Financial Officer recently sold US$292k worth of stock

CEO & Director recently sold US$2.2m worth of stock

CEO & Director recently sold US$2.2m worth of stock

New minor risk - Insider selling

Immunovant, Inc., Annual General Meeting, Aug 21, 2023

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell Small Cap Comp Value Index

Price target increased by 14% to US$28.23

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Chief Financial Officer recently sold US$52k worth of stock

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Price target increased by 11% to US$20.25

Insider recently sold US$188k worth of stock

Chief Development & Technology Officer recently sold US$1.0m worth of stock

Price target increased to US$13.00

Less than half of directors are independent

Price target increased to US$11.00

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Chief Financial Officer recently sold US$118k worth of stock

Immunovant stock down on raising $75M though equity capital

Executive Chairperson of the Board recently bought US$116k worth of stock

Immunovant, Inc. Announces IMVT-1402

Immunovant Announces Two New Development Programs for Batoclimab

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant, Inc., Annual General Meeting, Aug 17, 2022

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell 2000 Growth Index

Immunovant, Inc. Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease

Immunovant, Inc. to Report Q4, 2022 Results on Jun 08, 2022

Price target decreased to US$10.78

High number of new and inexperienced directors

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Price target decreased to US$11.25

Chief Medical Officer recently sold US$222k worth of stock

Price target decreased to US$12.25

Immunovant, Inc. Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022

Independent Director recently bought US$150k worth of stock

Independent Director recently bought US$54k worth of stock

Price target decreased to US$19.86